Alcon to Launch Clareon IOL at ESCRS Meeting

October 6, 2017: By Joan McKenna

alcon-large-3x2Alcon will introduce its new Clareon intraocular lens (IOL) at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, set for Oct. 7-11 in Lisbon, Portugal.

The company describes the Clareon as having the most advanced optic IOL material available. The lens is offered in an automated, disposable, preloaded delivery system.

Alcon, the Texas-based eye care division of Novartis, says it will provide an extensive scientific and educational program at the meeting, with 18 accepted abstracts and more than 10 satellite events.

“We are proud to deliver on our commitment to bring innovations to the surgical community, and Clareon is one of the biggest breakthroughs in the IOL space,” said Mike Ball, chief executive officer of Alcon. “This is a great year for Alcon as we celebrate many important milestones.”

Among those is the 100 millionth implantation of Alcon’s flagship AcrySof lens, Ball said.

Presentations also will include new efficacy and safety data for Alcon’s CyPass Micro-Stent in patients with glaucoma.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023